Hoba Therapeutics

📍 Copenhagen, Denmark🗓 Founded 2016👥 14 employees💰 Last funded Jan 2020
Biotechnology Research🌐 hobatherapeutics.com
Website LinkedIn
Hoba Therapeutics is a Danish biotech developing restorative treatments for chronic pain disorders and hearing loss. Both indications have a clear unmet medical need for safe and efficacious treatments for millions of patients worldwide. Hoba Therapeutics is developing HB-086 for the treatment of chronic neuropathic pain. HB-086 is a non-opioid compound with a unique mechanism of action targeting the peripheral nervous system to reverse neuropathic pain and the underlying cause of the disease. The second drug candidate HB-097 is a pharmacological treatment for sensorineural hearing loss. Preclinical data of HB-097 show both a preventive effect of hearing loss by protecting nerve cells and a regenerative effect by reversal of already induced damage. Hoba Therapeutics was founded in 2016 by Novo Holdings and Borean Innovation. Hoba Therapeutics received the Accelerator grant from the European Innovation Council in 2021 and the Grand Solution grant from Innovation Fund Denmark in 2018. About chronic neuropathic pain: Chronic neuropathic pain is a significant global health issue, affecting a substantial portion of the population worldwide. In Europe, the prevalence is estimated to be 6–8% of the general population. Chronic neuropathic pain represents an enormous personal and economic burden. Neuropathic pain is a chronic disorder resulting from damage or dysfunction of the nervous system. Causative factors are lesions in or disorders of the nervous system, such as injury, pressure, toxic agents (e.g., chemotherapy), viral infections, and metabolic disorders. These lesions lead to aberrant functioning of sensory nerve cells, resulting in a chronic, debilitating sensation of pain. The complexity and variability of chronic neuropathic pain necessitates a multifaceted treatment approach and highlights the need for a more effective and safer treatment options. The global neuropathic pain market is estimated to be valued at USD 7.6 bn.
3
Total investors
1
Early stage
2
Mid stage
0
Late stage
2016
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Denmark
3
Investor activity2016–2020 · investors recorded per year
201612019120201
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Hoba Therapeutics?
Hoba Therapeutics has 3 investors on record on gritt.io, including 1 early-stage backers, 2 mid-stage.
When did Hoba Therapeutics last raise funding?
The most recent investment in Hoba Therapeutics recorded on gritt.io was in January 2020.
When was Hoba Therapeutics founded?
Hoba Therapeutics was founded in 2016.
What industry is Hoba Therapeutics in?
Hoba Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Hoba Therapeutics based?
Hoba Therapeutics is headquartered in Copenhagen, Denmark.